On this episode, we sit down for a conversation with Cat Oyler, Global Head, Strategy & Operations at Johnson & Johnson, for a more personal story about how innovation in the R&D space is improving lives of those around the world.

On today's episode we sit down with Josh Ghaim, head of Consumer R&D here at Johnson & Johnson. We discuss healthcare and beauty trends that we found at CES while also getting some insight into how J&J is approaching these new technologies and making a name for themselves at CES.

On this episode of the J&J Innovation Podcast, Bill Martin, CSO of Blackthorn Therapeutics, talks about the work they are doing to change the way we think about drug development, specifically as it pertains to treating brain disorders.

Cynthia Burzell was a scuba diver and graduate student when she made a discovery that would change her academic – and professional – future. Learn more about how Cynthia – along with her business partner, Marilyn Bruno – turned an underwater discovery into a company that's trying to change how diseases are treated both near and far.

In two interviews, Janssen's Steve Wooding and Ben Weigand discuss the vision of a world without disease and the hidden costs of discovering a cure.

Julie Papanek Grant, a partner at tech & healthcare early stage venture capital fund Canaan, discusses what's on the horizon for healthcare

Seema Kumar re-joins Joe, Joe, and Brian to talk about the impact the Champions of Science program is already having. Plus, Dr. Paul Stoffels – Chief Scientific Officer at Johnson & Johnson – makes a surprise appearance to talk about why recognizing Champions of Science is so important for the future of healthcare.

Jeremiah Owyang, founder and CEO of CrowdCompanies, joins the podcast to talk about how big companies are changing the ways they think and act to enhance their own ability to innovate.

On this episode, we sit down with Gary Romano to learn more about the progress being made in the diagnosis and treatment of Alzheimers

On part 3 of our 3-part 'BIO Conference' Special we talk with Barry Springer to discuss how new ways of creating, developing, and funding drugs can speed our way into the age of individualized medicines.